WallStSmart

Abbott Laboratories (ABT)vsSouthern Copper Corporation (SCCO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 210% more annual revenue ($45.13B vs $14.55B). SCCO leads profitability with a 34.1% profit margin vs 13.9%. ABT appears more attractively valued with a PEG of 1.29. SCCO earns a higher WallStSmart Score of 65/100 (B-).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.0Quality: 4.8
Piotroski: 3/9

SCCO

Strong Buy

65

out of 100

Grade: B-

Growth: 9.3Profit: 10.0Value: 3.7Quality: 6.8
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTUndervalued (+0.6%)

Margin of Safety

+0.6%

Fair Value

$87.53

Current Price

$84.32

$3.21 discount

UndervaluedFair: $87.53Overvalued

Intrinsic value data unavailable for SCCO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$151.56B9/10

Large-cap with strong market position

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

SCCO6 strengths · Avg: 9.8/10
Return on EquityProfitability
46.3%10/10

Every $100 of equity generates 46 in profit

Profit MarginProfitability
34.1%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
58.3%10/10

Strong operational efficiency at 58.3%

Revenue GrowthGrowth
36.2%10/10

Revenue surging 36.2% year-over-year

EPS GrowthGrowth
66.7%10/10

Earnings expanding 66.7% YoY

Market CapQuality
$148.31B9/10

Large-cap with strong market position

Areas to Watch

ABT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

SCCO3 concerns · Avg: 3.3/10
P/E RatioValuation
30.1x4/10

Premium valuation, high expectations priced in

Price/BookValuation
13.0x4/10

Trading at 13.0x book value

PEG RatioValuation
5.412/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : SCCO

The strongest argument for SCCO centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 34.1% and operating margin at 58.3%. Revenue growth of 36.2% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are Piotroski F-Score, EPS Growth.

Bear Case : SCCO

The primary concerns for SCCO are P/E Ratio, Price/Book, PEG Ratio.

Key Dynamics to Monitor

ABT profiles as a value stock while SCCO is a growth play — different risk/reward profiles.

SCCO carries more volatility with a beta of 1.08 — expect wider price swings.

SCCO is growing revenue faster at 36.2% — sustainability is the question.

SCCO generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

SCCO scores higher overall (65/100 vs 56/100), backed by strong 34.1% margins and 36.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Southern Copper Corporation

BASIC MATERIALS · COPPER · USA

Southern Copper Corporation is engaged in the extraction, exploration, smelting and refining of copper and other minerals in Peru, Mexico, Argentina, Ecuador and Chile.

Visit Website →

Want to dig deeper into these stocks?